Lumida
/NKTR
⌘K
Nektar Therapeutics

Nektar Therapeutics

NKTR
$68.26USD↑+1.80%+1.21 today

MARKET CAP

2.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$66 – $69

52W RANGE

$21
$109

AI Summary

Stalk
StalkMedium

NKTR is in Stage 2 with a corrective reset showing higher highs and higher lows above repaired EMA support. Bullish medium-term bias is reinforced by a Bullish Pivot Point and continuation structure, but short-term timing remains neutral as price pulls back into rising EMAs and the 50 DMA. Execution posture is to stalk and await acceptance at the EMA/50 DMA support zone before engaging on the long side.

  • ↑Phase II RESPEG trials demonstrate durable and deepening responses
  • ↑Ended Q1 2026 with >$1 B cash, funding Phase III development
  • ↓Q1 net loss of $44.9 M far exceeds $10.5 M revenues
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Nektar Therapeutics (NASDAQ: NKTR) is an emerging biopharmaceutical company focused on developing innovative therapies targeting autoimmune and inflammatory diseases, specifically utilizing T regulatory cell (Treg) modulation through its lead product, RESPEG. Positioned in a rapidly evolving immunology landscape, the company aims to capture substantial market share in indications such as atopic dermatitis and alopecia areata, addressing significant limitations of existing therapies with its unique drug delivery and efficacy approaches.

Bull says

  • ↑Phase II RESPEG trials demonstrate durable and deepening responses
  • ↑Ended Q1 2026 with >$1 B cash, funding Phase III development
  • ↑FDA fast-track for atopic dermatitis and alopecia areata
  • ↑Eczema market projected at ~$35 B by mid-2030s
  • ↑High institutional ownership indicates investor confidence
  • ↑Strong momentum factors and favorable earnings revisions

Bear says

  • ↓Q1 net loss of $44.9 M far exceeds $10.5 M revenues
  • ↓R&D spend of $110–120 M in 2026 intensifies cash burn
  • ↓Short interest at 1.04 and insider sales raise volatility
  • ↓FDA approval timeline remains uncertain, regulatory hurdles possible
  • ↓Weak profitability factors and elevated leverage risk deter investors
  • ↓Strong competition from established immunology therapies limits upside

Investment themes with NKTR

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026neutral

Transcript signals

Bull points

  • EZ75, the EZ100, and the VIGA01
  • highly informative
  • you know, durability for potentially, you know, nine to 12 months off therapy

Bear points

  • placebo effect for alopecia areata for patients who have severe and very severe disease is very low
  • placebo effect could be higher in the population of patients that have, say, you know, a SALT score that's actually less than 50, so in the 30 to 50 range
  • placebo effect for alopecia areata for patients who have severe and very severe disease is very low
Read full transcript analysis ›